These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 10425338)

  • 1. Delivery of glipizide from asymmetric membrane capsules using encapsulated excipients.
    Thombre AG; DeNoto AR; Gibbes DC
    J Control Release; 1999 Aug; 60(2-3):333-41. PubMed ID: 10425338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation and evaluation of extended release asymmetric membrane capsules of atenolol.
    Guarve K; Gupta GD
    Curr Drug Deliv; 2011 Mar; 8(2):159-63. PubMed ID: 21235475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel design of osmotic chitosan capsules characterized by asymmetric membrane structure for in situ formation of delivery orifice.
    Wang GM; Chen CH; Ho HO; Wang SS; Sheu MT
    Int J Pharm; 2006 Aug; 319(1-2):71-81. PubMed ID: 16701971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In situ-formed asymmetric membrane capsule for osmotic release of poorly water-soluble drug.
    Philip A; Pathak K
    PDA J Pharm Sci Technol; 2007; 61(1):24-36. PubMed ID: 17390701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymmetric membrane capsules for delivery of poorly water-soluble drugs by osmotic effects.
    Wang CY; Ho HO; Lin LH; Lin YK; Sheu MT
    Int J Pharm; 2005 Jun; 297(1-2):89-97. PubMed ID: 15885936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel asymmetric membrane osmotic pump capsule with in situ formed delivery orifices for controlled release of gliclazide solid dispersion system.
    Yang Y; Zhao Z; Wang Y; Yang L; Liu D; Yang X; Pan W
    Int J Pharm; 2016 Jun; 506(1-2):340-50. PubMed ID: 27132166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osmotically regulated floating asymmetric membrane capsule for controlled site-specific delivery of ranitidine hydrochloride: optimization by central composite design.
    Chauhan MS; Kumar A; Pathak K
    AAPS PharmSciTech; 2012 Dec; 13(4):1492-501. PubMed ID: 23104305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and evaluation of osmotically controlled oral drug delivery system of glipizide.
    Verma RK; Garg S
    Eur J Pharm Biopharm; 2004 May; 57(3):513-25. PubMed ID: 15093601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experiment on formulation and drug release behavior of porosity asymmetric membrane capsules in vitro.
    Fu HX; Li H; Zhang FZ; Zhao YZ; Wan CW; Chen MT; Jia XC; Yan L; Sun CC; Xu YY
    Drug Dev Ind Pharm; 2012 Jun; 38(6):670-8. PubMed ID: 22469006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled release matrix tablets of glipizide: Influence of different grades of ethocel and Co-excipient on drug release.
    Mehsud SU; Khan GM; Hussain A; Akram M; Akhlaq M; Khan KA; Shakoor A
    Pak J Pharm Sci; 2016 May; 29(3):779-87. PubMed ID: 27166548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigations on the drug releasing mechanism from an asymmetric membrane-coated capsule with an in situ formed delivery orifice.
    Lin YK; Ho HO
    J Control Release; 2003 Apr; 89(1):57-69. PubMed ID: 12695063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetric membrane capsules of phenylephrine hydrochloride: an osmotically controlled drug delivery system.
    Kumar A; Philip AK; Pathak K
    Curr Drug Deliv; 2011 Sep; 8(5):474-82. PubMed ID: 21696358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel solubility-modulated granules through porosity osmotic pump for controlled carvedilol delivery.
    Song QL; Li P; Li YM
    Pharm Dev Technol; 2012; 17(6):666-76. PubMed ID: 21486184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synchronized and controlled release of metformin hydrochloride/glipizide from elementary osmotic delivery.
    Pan H; Jing H; Yang X; Pan W; Chen T
    Drug Dev Ind Pharm; 2017 May; 43(5):780-788. PubMed ID: 27278057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and in vitro characterization of a non-effervescent floating drug delivery system for poorly soluble drug, glipizide.
    Meka VS; Pillai S; Dharmalingham SR; Sheshala R; Gorajana A
    Acta Pol Pharm; 2015; 72(1):193-204. PubMed ID: 25850215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of controlled release osmotic pump tablet of glipizide solid dispersion.
    Patel GC; Asodaria KV; Patel HP; Shah DR
    Curr Drug Deliv; 2014; 11(6):817-27. PubMed ID: 23859357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug release and swelling kinetics of directly compressed glipizide sustained-release matrices: establishment of level A IVIVC.
    Sankalia JM; Sankalia MG; Mashru RC
    J Control Release; 2008 Jul; 129(1):49-58. PubMed ID: 18456362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of excipients, drugs, and osmotic agent in the inner core on the time-controlled disintegration of compression-coated ethylcellulose tablets.
    Lin SY; Lin KH; Li MJ
    J Pharm Sci; 2002 Sep; 91(9):2040-6. PubMed ID: 12210050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osmotically regulated flow of flurbiprofen through in situ formed asymmetric membrane capsule.
    Philip AK
    Curr Drug Deliv; 2008 Apr; 5(2):127-32. PubMed ID: 18393815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osmotic pellet system comprising osmotic core and in-process amorphized drug in polymer-surfactant layer for controlled delivery of poorly water-soluble drug.
    Saindane N; Vavia P
    J Pharm Sci; 2012 Sep; 101(9):3169-79. PubMed ID: 22418998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.